Please provide your email address to receive an email when new articles are posted on . Multiple system atrophy — whose worldwide awareness day is commemorated every Oct. 3 — includes disorders that ...

The fundamental cause of multiple system atrophy (MSA) is a loss of oligodendroglial and neuronal cells in the brain and central nervous system. The loss of cells is gradual and progressive, leading ...

Multiple system atrophy (MSA) is a neurodegenerative disease that affects involuntary body functions such as blood pressure and heart rate as well as movement. It is similar to Parkinson's disease, ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Longtime Texas high school football coach Mike Robinson has died, DeSoto coach Claude Mathis confirmed to The Dallas Morning ...

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

In the past, researchers believed that Parkinson's disease did not affect life expectancy. But recent studies showed a somewhat shorter life span. Now a new study suggests that when the disease does ...

The Food and Drug Administration (FDA) has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy. The Food and Drug Administration (FDA) has ...